Abstract: A compound of formula (I-1), or a pharmaceutically accept able salt or hydrate thereof, formula (I-1) wherein: ring A is a monocyclic 5, 6, or 7-membered heterocycloalkyl ring optionally substituted by one or more substituents selected from alkyl, CN, cycloalkyl, OH, alkoxy, halo, haloalkyl and heteroaryl, wherein said heteroaryl group is in turn optionally further substituted with one or more groups selected from halo and alkyl, and wherein one or two carbons in the 5, 6, or 7-membered heterocycloalkyl ring are optionally replaced by a group selected from O, NH, S and CO; L is a linker group which is a 2 to 7-membered saturated or unsaturated aliphatic group, wherein one or two carbon atoms in said group, other than the carbon atom directly bonded to ring A, are optionally replaced by a heteroatom-containing group selected from O, NH and S, and wherein when two carbon atoms are replaced, the heteroatom-containing groups are separated by at least two carbon atoms and the linker group is at least a 5-membered
Type:
Grant
Filed:
September 21, 2021
Date of Patent:
October 27, 2026
Assignee:
Grey Wolf Therapeutics Limited
Inventors:
Martin Quibell, Jason John Shiers, Michael Sparenberg, Eleanor Ivens
Abstract: Disclosed are lithium difluoro-bis(oxalate)phosphate, a preparation method therefor, and an application thereof. The preparation method comprises the following steps: (1) mixing oxalyl chloride and lithium hexafluorophosphate with a nonaqueous solvent, adding siloxane, and reacting to obtain a lithium difluoro-bis(oxalate)phosphate solution; and (2) adding a poor solvent into the lithium difluoro-bis(oxalate)phosphate solution for crystallization treatment to obtain the lithium difluoro-bis(oxalate)phosphate. According to the present application, raw materials such as lithium hexafluorophosphate, oxalyl chloride, and hexamethyldisiloxane are used for preparing the difluoro-bis(oxalate)phosphate, and the method of the present application is few in side reaction, few in impurities, high in product purity, and suitable for industrial production.
Abstract: The present invention relates to structured molecular vectors of formula (I), compounds of formula (II) and pharmaceutical compositions comprising such compounds. The invention also relates to such pharmaceutical compositions for use for preventing and/or treating a disease chosen among an inflammatory disease or a disease associated with a cognitive disorder. The invention further relates to such pharmaceutical compositions for use for preventing cognitive decline or restoring cognitive functions altered in brain injuries and/or in traumatic brain injuries and/or in a neuroinflammatory disease, and/or in a neurodegenerative disease.
Type:
Grant
Filed:
February 21, 2020
Date of Patent:
October 20, 2026
Assignees:
Universite Claude Bernard Lyon 1, Centre National de la Recherche Scientifique, Institut National de la Sante et de la Recherche Medicale, Universite Jean Monnet Saint Etienne
Inventors:
Jacques Bodennec, Amor Belmeguenaï, Selena Bodennec, Laurent Bezin, Béatrice Georges, Victor Blot
Abstract: The present disclosure is directed to a method of dose initiation for an aripiprazole treatment to a patient in need thereof; the patient is administered two, separate 100 to 500 mg injections of an aripiprazole intramuscular (IM) depot formulation at separate gluteal and/or deltoid injection sites, and a single dose of oral aripiprazole. The administration occurs on a first day of the treatment.
Type:
Grant
Filed:
June 3, 2024
Date of Patent:
October 13, 2026
Assignee:
Otsuka Pharmaceutical Co., Ltd.
Inventors:
Matthew Harlin, Xiaofeng Wang, Yanlin Wang, Arash Raoufinia
Abstract: Disclosed herein are pharmaceutical compositions and dosage forms including N-[5-(3,5-difluorobenzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-2H-pyran-4-ylamino) benzamide that are useful in the treatment of subjects having cancer. The present disclosure also provides methods for preparing these pharmaceutical compositions and dosage forms, and methods of treating subjects having cancer utilizing the pharmaceutical compositions and dosage forms provided herein.
Abstract: This disclosure provides a method of safely and rapidly initiating or escalating oral sotalol therapy by administering an intravenous dosage of sotalol followed by oral sotalol twice daily.
Type:
Grant
Filed:
May 23, 2023
Date of Patent:
September 22, 2026
Assignee:
AltaThera Pharmaceuticals LLC
Inventors:
John Charin Somberg, Brandon Ira Kashfian, Janos Molnar
Abstract: The present invention relates to the field of chemical pharmacy, relates to a crystal form of a pyrimidine derivative and a preparation method therefor, and specifically relates to crystal forms A, B, C, D, and E of a compound of formula (I), a preparation method therefor, and a pharmaceutical composition and use thereof. The present invention solves the problems of small granularity, poor fluidity, poor stability and the like of the compound of formula (I) present in an amorphous form. The crystal form prepared by the present invention and the pharmaceutical composition thereof can be used for preparing a drug for treating a cancer disease.
Type:
Grant
Filed:
June 21, 2022
Date of Patent:
September 22, 2026
Assignee:
ZHEJIANG HISUN PHARMACEUTICAL CO., LTD.
Inventors:
Meiyu Zhao, Lianwei Chen, Na Li, Zhenjuan Shi, Jianfeng Zheng, Di Su
Abstract: The invention relates to a pharmaceutically acceptable acid addition salt of: (i) S-oxprenolol; and (ii) phosphoric acid. Medical uses of the salt and compositions comprising the salt are also described.
Type:
Grant
Filed:
April 7, 2025
Date of Patent:
September 1, 2026
Assignee:
ACTIMED THERAPEUTICS LTD
Inventors:
Melissa Joseph, Ronnie Maxwell Lawrence, Elaine Morten, Saurabh Chitre, Natalie Louise Kelk, Craig Callahan
Abstract: Cinnamoyl amino acid compounds and a use thereof, which relate to the fields of medicinal chemistry and pharmacotherapeutics, and specifically relate to cinnamoyl amino acid compounds having inducible nitric oxide synthase (iNOS) inhibitory activity or a pharmaceutically acceptable salt thereof, a pharmaceutical composition including the compounds, and a medical use thereof, particularly an application thereof in the prevention and treatment of neurodegenerative diseases related to nerve cell damage, including ischemic stroke, Parkinson's disease, and so on.
Abstract: The disclosure provides a lyophilized preparation of prostaglandin E1 methyl ester for injection and production and use thereof. The lyophilized preparation comprises the following components by weight: 0.1-10 parts of prostaglandin E1 methyl ester, 500-4000 parts of an oil for injection, 500-2000 parts of an emulsifier, 0-10 parts of a co-emulsifier, 5000-50000 parts of a lyoprotectant, and 200-1500 parts of glycerin. The prostaglandin E1 methyl ester lyophilized agent of the disclosure has less blood vessel irritation, good drug stability, and superior drug activity and therapeutic effect than similar prostaglandin E1 products.
Type:
Grant
Filed:
October 28, 2019
Date of Patent:
August 18, 2026
Assignee:
Xi'an Hanfeng Pharmaceutical Co., Ltd.
Inventors:
Rutao Wang, Long An, Yi Zhao, Jinghua Pang, Tao Chen
Abstract: The present invention provides formulations that enhances bioavailability of thromboxane receptor antagonists allowing them to bind to the thromboxane A2 receptors in subjects suffering from disease indications in which the prostanoid thromboxane A2, and incidental thromboxane A2 receptor ligands, are implicated. The formulations comprise a solid dispersion comprising a benzenesulfonyl urea and a polymer that are suitable for administration through oral or other routes of delivery.
Type:
Grant
Filed:
July 6, 2021
Date of Patent:
August 18, 2026
Assignee:
ATXA THERAPEUTICS LIMITED
Inventors:
B. Therese Kinsella, Helen Reid, Eamon Mulvaney
Abstract: The present invention provides compounds of Formula (I): or a pharmaceutically acceptable salt thereof, useful as inhibitors of PAD4, compositions thereof, and methods of treating PAD4-related disorders. Variables rings A, B, R1, R3, R8, and other variables are as defined herein.
Abstract: Pharmaceutical compositions of colchicine for once-a-day oral administration are provided. The formulations comprise a sustained-release component and an optional immediate-release component, the compositions of which can be selectively adjusted, respectively, to release the active ingredient along a pre-determined or desired release profile. Methods of treating or preventing cardiovascular disease and/or inflammatory disease in mammalian subjects comprising the administration of the novel formulations disclosed herein are also provided.
Abstract: The present disclosure encompasses solid state forms of AT-001, in embodiments crystalline polymorphs of AT-001 or salts or co-crystals of AT-001, processes for preparation thereof, and pharmaceutical compositions thereof.
Type:
Grant
Filed:
September 7, 2021
Date of Patent:
June 23, 2026
Assignee:
ASSIA CHEMICAL INDUSTRIES LTD.
Inventors:
Anantha Rajmohan Muthusamy, Amit Singh, Yogesh Dhananjay Wagh
Abstract: Compositions comprising aldehyde functional monoterpenoids in combination with 3,3?,4?,7-tetrahydroxyflavone, zinc, and a 5-beta-D-Ribofuranosylpicolineamide adenine-dinucleotide molecule are provided for treating viral infections, e.g., coronavirus infections such as COVID-19, and/or enhancing mood.
Abstract: Disclosed herein are antimicrobial compounds compositions, pharmaceutical compositions, the method of use and preparation thereof. Some embodiments relate to boronic acid derivatives and their use as therapeutic agents, for example, ?-lactamase inhibitors (BLIs).
Abstract: 1. The present invention relates to the crystal of compound X7 hydrochloride and its preparation method and application. The 2? diffraction angle of the X-ray powder diffraction diagram of the crystal of compound X7 hydrochloride exhibits characteristic diffraction peaks in the range of 5°˜35°. The crystal of the compound X7 hydrochloride has better physical and chemical properties.
Abstract: The present invention provides compounds of formula I or II: wherein X1, R1 and R2 are as described herein, as well as pharmaceutically acceptable salts thereof. Further the present invention is concerned with the manufacture of the compounds of formula I, pharmaceutical compositions comprising them and their use as medicaments.
Type:
Grant
Filed:
July 28, 2023
Date of Patent:
May 19, 2026
Assignee:
HOFFMANN-LA ROCHE INC.
Inventors:
Andrew Simon Bell, Jérémy Besnard, Anthony Richard Bradley, Luke Green, Wolfgang Haap, Buelent Kocer, Andreas Kuglstatter, Xavier Lucas, Patrizio Mattei, Dmitry Mazunin, Claus Riemer, Willem Paul Van Hoorn
Abstract: Novel cromolyn analogs useful as imaging agents for detecting atherosclerotic plaques and for treating atherosclerosis and Alzheimer's Disease, and methods of making the cromolyn analogs, are disclosed. The cromolyn analogs have the general formula: wherein X is OH, C1-C6 alkoxyl; Y and Z are independently selected from a C1-C6 alkyl, C1-C6 alkoxyl, halogen, un-substituted or C1-C6 substituted amine, 18F, 19F, or H; and n is 1, 2 , or 3; and wherein for structure (I), if n are both 1 and Y and Z are both H and X is OH.